According to a report published in Brazil Pharma News, and recently cited by thepharmaletter, Brazil is failing to produce the number of APIs required to produce the drugs it needs. The nation is the sixth largest pharma market in the world, according to IMS Health, but currently makes only about 1% of its APIs. Brazil's Oswaldo Cruz Foundation has been researching this issue for some time, and recently mapped Brazilian pharma's manufacturing, technical and investmentcapacity in this area. The research aims to help create a more effective industrial policy for the pharmaceuticals sector.
Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016 Embracing the process as a means to a strong quality culture